Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
Genome and transcriptome sequences from hundreds of pediatric cancer cases led to somatic mutations and fusions suspected of producing potentially targetable antigens.
Earlier this week, the company's scientific co-founders published an improved version of the ATAC-seq method that allows them to analyze frozen tissue.
The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.
The partners aim to enable the early prediction of clinical efficacy of Alligator's pipeline candidates by analyzing potential systemic biomarkers.
The National Cancer Institute-led team used a CRISPR-based approach to identify genes like APLNR that, when mutated, make cancers resistant to immunotherapy.
Adaptive will work with NCI's Cancer Therapy Evaluation Program to use its ImmunoSeq platform for biomarker discovery in clinical trials.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
Neon Therapeutics is sponsoring a Phase Ib trial of neoantigen-based vaccines in combination with anti-PD-1 treatment in melanoma, lung cancer, and bladder cancer.
The two companies plan to combine their respective gene editing and neoantigen discover technologies in order to develop new T cell therapies for cancer patients.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.